Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

“Commonly known as the stomach flu, norovirus has been around forever, and has become the leading cause of gastroenteritis or ...

The mRNA-1273.815 vaccine provided significant protection against COVID-19-related hospitalizations and medically attended COVID-19 among US adults.

of an Epstein-Barr virus (EBV) vaccine candidate yesterday. The EBV vaccine is being developed in collaboration with Merck, which is known as MSD outside the United States and Canada. Per ...

Epstein-Barr virus and HIV are other programs that are likely to be defined by their complexity, which could make it difficult for other non-mRNA vaccines to compete. In oncology, Moderna aims to ...

The COVAIL trial reveals that neutralizing antibody titers correlate with COVID-19 risk reduction after mRNA boosters. Learn how this impacts vaccine strategies against emerging variants.

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

But these vaccines have not yet been tested in a clinical trial, since there have not been enough H5N1 infections in humans to compare vaccinated people to unvaccinated. What about an mRNA vaccine ...

Moderna also saw positive Phase I/II data with other infectious disease vaccines, namely the mRNA-1189 for Epstein-Barr virus (EBV), mRNA-1468 for varicella-zoster virus (VZV) to prevent shingles ...